全文获取类型
收费全文 | 390篇 |
免费 | 24篇 |
国内免费 | 10篇 |
专业分类
儿科学 | 7篇 |
妇产科学 | 2篇 |
基础医学 | 49篇 |
口腔科学 | 2篇 |
临床医学 | 27篇 |
内科学 | 116篇 |
皮肤病学 | 22篇 |
神经病学 | 43篇 |
特种医学 | 25篇 |
外科学 | 42篇 |
综合类 | 1篇 |
预防医学 | 9篇 |
眼科学 | 2篇 |
药学 | 17篇 |
肿瘤学 | 60篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 24篇 |
2020年 | 8篇 |
2019年 | 16篇 |
2018年 | 13篇 |
2017年 | 16篇 |
2016年 | 16篇 |
2015年 | 16篇 |
2014年 | 15篇 |
2013年 | 13篇 |
2012年 | 28篇 |
2011年 | 33篇 |
2010年 | 6篇 |
2009年 | 9篇 |
2008年 | 16篇 |
2007年 | 26篇 |
2006年 | 27篇 |
2005年 | 33篇 |
2004年 | 13篇 |
2003年 | 17篇 |
2002年 | 17篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 5篇 |
1998年 | 6篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1993年 | 5篇 |
1992年 | 1篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1962年 | 1篇 |
排序方式: 共有424条查询结果,搜索用时 15 毫秒
11.
12.
Kitabatake S Niwa Y Goto H 《Nihon rinsho. Japanese journal of clinical medicine》2005,63(8):1434-1437
The treatment of Barrett's esophagus is controversial. Current treatments include endoscopic therapy, surgical procedures, gastric acid-suppressive therapy with proton pump inhibitors (PPIs), and cancer chemoprevention such as nonsteroidal anti-inflammatory drugs. Endoscopic therapy combined with gastric acid suppressive therapy can result in squamous reepithelialization of the Barrett's mucosa. Antireflux surgery and PPIs therapy are potential options for the treatment of gastroesophageal reflux symptoms in patients with Barrett's esophagus. But there are no prospective studies that support any alternative approach to treatment. Although chemoprevention therapy may reduce cancer risk in Barrett's esophagus, no randomized controlled trials that prove its efficacy have been reported. 相似文献
13.
Toyoda H Kumada T Kiriyama S Sone Y Tanikawa M Hisanaga Y Hayashi K Honda T Kitabatake S Kuzuya T Nonogaki K Kasugai T Shimizu J 《Cancer》2004,100(11):2415-2421
BACKGROUND: The authors analyzed changes in the characteristics and survival rate of patients with hepatocellular carcinoma (HCC) in the past 25 years. METHODS: Trends in clinical characteristics and survival rate of patients with HCC were evaluated retrospectively based on data from 1365 patients who were diagnosed, treated, and followed between 1976 and 2000. RESULTS: Between 1976-1995, the number of patients with smaller tumors, a less advanced tumor stage, and with a lower Child-Pugh class increased markedly. No differences were observed in the distributions of these three factors between the periods 1991-1995 and 1996-2000. The year of HCC diagnosis, tumor size, tumor stage, Child-Pugh class, and the kind of initial treatment received correlated significantly with patient survival rates by multivariate analysis. The year of HCC diagnosis was found to contribute independently to the improvement in patient survival rates. Using the Kaplan-Meier comparison, the time periods during which the highest patient survival rates occurred were found to be 1991-1995/1996-2000, 1986-1990, and 1976-1985, in that order. The authors did not observe a difference with regard to survival rates between patients in the 1991-1995 and 1996-2000 groups. CONCLUSIONS: The characteristics of patients with HCC changed dramatically from 1976 to 1995 (but not in the past 10 years) toward the earlier detection of HCC. This contributed to the improvement noted in patient survival rates during this period. The year of HCC diagnosis was found to be an independent factor for the improved survival rates by multivariate analysis. This indicated that the progress of treatment and care for patients with HCC contributed to the annual improvement in patient survival rates. 相似文献
14.
Shishido Y Tanaka T Tanabe S Furushiro M Hashimoto S Yokokura T Shibata S Watanabe S 《Pharmaceutical research》1999,16(3):463-465
Pharmaceutical Research - 相似文献
15.
Yasui T Maegawa M Tomita J Miyatani Y Yamada M Uemura H Ueno S Numata S Ohmori T Tsuchiya N Yuzurihara M Takeda S Irahara M 《Journal of reproductive immunology》2007,75(1):56-62
OBJECTIVE: The purpose of the present study was to clarify the association of serum cytokine concentrations, determined using a multiplexed cytokine assay, with psychological symptoms in midlife women. METHODS: Fifty-three peri- and post-menopausal women with and without psychological symptoms in Greene's climacteric scale were enrolled in this study. Levels of 17 cytokines in serum samples were measured simultaneously using a multiplexed human cytokine assay. RESULTS: Serum interleukin (IL)-6 concentration in women with psychological symptoms (2.71+/-047 pg/ml) was significantly (p=0.009) higher than that in women without psychological symptoms (0.98+/-0.18 pg/ml). Serum IL-8 concentration in women with psychological symptoms (33.4+/-8.17 pg/ml) was also significantly (p=0.022) higher than that in women without psychological symptoms (7.87+/-1.64 pg/ml). In addition, serum IL-10 concentration in women with psychological symptoms (0.74+/-0.26 pg/ml) was significantly (p=0.048) higher than that in women without psychological symptoms (0.07+/-0.04 pg/ml). Tumor necrosis factor (TNF)-alpha in serum was detected only in women with psychological symptoms. Serum IL-2 concentration in women with psychological symptoms tended (p=0.066) to be higher than that in women without psychological symptoms. No significant differences were found between levels of other cytokines in women with and without psychological symptoms. CONCLUSION: Psychological stress manifested as climacteric symptoms in midlife women may be associated with increases in serum concentrations of IL-6, IL-8, IL-10, and TNF-alpha. 相似文献
16.
Kenya Kusunose Yuichiro Okushi Yoshihiro Okayama Robert Zheng Miho Abe Michikazu Nakai Yoko Sumita Takayuki Ise Takeshi Tobiume Koji Yamaguchi Shusuke Yagi Daiju Fukuda Hirotsugu Yamada Takeshi Soeki Tetsuzo Wakatsuki Masataka Sata 《Nutrients》2021,13(2)
A broad range of chronic conditions, including heart failure (HF), have been associated with vitamin D deficiency. Existing clinical trials involving vitamin D supplementation in chronic HF patients have been inconclusive. We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). After exclusion criteria, we identified 93,692 patients who were first hospitalized with HF between April 2012 and March 2017 (mean age was 79 ± 12 years, and 52.2% were male). Propensity score (PS) was estimated with logistic regression model, with vitamin D supplementation as the dependent variable and clinically relevant covariates. On PS-matched analysis with 10,974 patients, patients with vitamin D supplementation had lower total in-hospital mortality (6.5 vs. 9.4%, odds ratio: 0.67, p < 0.001) and in-hospital mortality within 7 days and 30 days (0.9 vs. 2.5%, OR, 0.34, and 3.8 vs. 6.5%, OR: 0.56, both p < 0.001). In the sub-group analysis, mortalities in patients with age < 75, diabetes, dyslipidemia, atrial arrhythmia, cancer, renin-angiotensin system blocker, and β-blocker were not affected by vitamin D supplementation. Patients with vitamin D supplementation had a lower in-hospital mortality for HF than patients without vitamin D supplementation in the propensity matched cohort. The identification of specific clinical characteristics in patients benefitting from vitamin D may be useful for determining targets of future randomized control trials. 相似文献
17.
Intravesical prostatic protrusion is not always the same shape: Evaluation by preoperative cystoscopy and outcome in HoLEP 下载免费PDF全文
18.
19.
20.
Goro Kominami Shusuke Mori Keiko Sagawa Ken'Ichi Igano Ken Inouye Masao Kono 《Journal of immunoassay & immunochemistry》2013,34(3-4):229-243
Abstract A highly specific and sensitive competitive radioimmunoassay was developed for caerulein (CLN), an analogue of cholecystokinin-8 (CCK-8), in plasma and brain. Antiserum was produced in rabbit by immunization with Nδ-[CLN-(1-6)]-ornithine amide conjugated with bovine serum albumin by the glutaraldehyde method. Nα-[CLN-(1-6)]-lysine amide was labelled with 125I-Bolton & Hunter reagent and used as a labelled antigen after purification by high-performance liquid chromerography. This assay was highly specific for CLN, and cross reactivities for other related peptides, CCK-4, CCK-8, gastrin-I, and gastrin-(14–17), were not observed (<0.01%). The limits of determination in biological specimens after CLN administration were 11 pg/ml in human plasma and rat plasma and 80 pg/g in rat brain. This study showed that the slight structure difference between hapten and 125I-labelled antigen is important to the assay performance. 相似文献